Contributors |
|
xi | |
|
I Phytopharmaceuticals and technology |
|
|
|
1 General principle of primary and secondary plant metabolites: Biogenesis, metabolism, and extraction |
|
|
|
Charles Oluwaseun Aderunji |
|
|
|
|
|
|
Chioma Bertha Ehis-Eriakha |
|
|
|
|
|
4 | (1) |
|
|
4 | (3) |
|
1.3 Biogenesis of primary and secondary plant metabolites |
|
|
7 | (3) |
|
1.4 Medicinal potentials of plant secondary metabolites |
|
|
10 | (4) |
|
1.5 Processing, extraction, and isolation of plant metabolites |
|
|
14 | (3) |
|
|
17 | (1) |
|
|
17 | (8) |
|
|
17 | (8) |
|
2 Phytopharmaceuticals: Efficacy, safety, and regulation |
|
|
|
|
|
|
|
|
|
25 | (1) |
|
2.2 Efficacy and safety aspects of phytopharmaceuticals |
|
|
26 | (2) |
|
2.3 Phytopharmaceutical mechanisms of action at a molecular level |
|
|
28 | (6) |
|
2.4 Safety profile of phytopharmaceuticals |
|
|
34 | (1) |
|
2.5 Industrialization of phytopharmaceuticals |
|
|
35 | (1) |
|
2.6 Regulation of phytopharmaceuticals products |
|
|
35 | (1) |
|
2.7 Conclusion and future prospects |
|
|
36 | (3) |
|
|
36 | (3) |
|
3 Phytomedicine: Scope and current highlights |
|
|
|
|
|
39 | (1) |
|
3.2 Historical perspective |
|
|
40 | (2) |
|
3.3 Science technologies and phytomedicine: Present scenario |
|
|
42 | (1) |
|
3.4 Confronts in phytomedicine |
|
|
43 | (3) |
|
3.5 Plants and phytomedicine: Coupling plant physiology and biochemistry to human healthiness |
|
|
46 | (5) |
|
3.6 Phytomedicine: From secondary metabolites to biological activities |
|
|
51 | (1) |
|
|
51 | (4) |
|
|
52 | (1) |
|
|
52 | (3) |
|
4 Ancient and modern practices in phytomedicine |
|
|
|
|
|
55 | (1) |
|
|
55 | (6) |
|
4.3 Practice in various parts of the world |
|
|
61 | (1) |
|
|
62 | (2) |
|
4.5 Application of phytomedicine in real life |
|
|
64 | (5) |
|
4.6 Novel bioactive compounds of medicinal importance |
|
|
69 | (1) |
|
4.7 Modern methods in phytomedicine |
|
|
69 | (1) |
|
4.8 Ethics in phytomedicine |
|
|
70 | (1) |
|
4.9 Conclusion and future scenario |
|
|
71 | (7) |
|
|
71 | (7) |
|
|
|
|
|
Godswill Ntsomboh-Ntsefong |
|
|
|
|
|
|
|
78 | (1) |
|
5.2 Concerns in the use of herbal medicines |
|
|
79 | (1) |
|
5.3 Shortcomings and safety issues |
|
|
80 | (1) |
|
5.4 Analytical profile of some herbal medicines |
|
|
80 | (2) |
|
5.5 Standardization of herbal drugs |
|
|
82 | (1) |
|
5.6 Chromatographic fingerprint analysis: Techniques and classification |
|
|
83 | (1) |
|
|
83 | (6) |
|
|
84 | (5) |
|
6 Herbal remedies, toxicity, and regulations |
|
|
|
|
|
|
89 | (1) |
|
6.2 Importance of herbal therapies |
|
|
90 | (4) |
|
6.3 Herbs versus conventional drugs |
|
|
94 | (1) |
|
6.4 Efficacy and safety of herbal medicine |
|
|
95 | (5) |
|
6.5 Validation of herbal therapies |
|
|
100 | (2) |
|
6.6 Toxicity and interactions of herbal preparations |
|
|
102 | (8) |
|
6.7 Adverse reactions of selected herbal remedies |
|
|
110 | (3) |
|
6.8 General concept of evaluation and quality control assessment by drug regulations |
|
|
113 | (2) |
|
6.9 Herbal drug regulation in India |
|
|
115 | (1) |
|
6.10 Summary and conclusion |
|
|
116 | (13) |
|
|
117 | (12) |
|
|
|
|
|
|
|
|
|
|
129 | (2) |
|
|
131 | (4) |
|
7.3 Advantages of herbal over conventional cosmetics |
|
|
135 | (1) |
|
7.4 Applications of herbal products in cosmetics |
|
|
136 | (3) |
|
7.5 Ayurvedic concepts in herbal cosmeticology |
|
|
139 | (1) |
|
|
139 | (3) |
|
7.7 Preparations of herbal cosmetics |
|
|
142 | (3) |
|
7.8 Plants/botanicals for skin care |
|
|
145 | (4) |
|
7.9 Plant metabolites and uses |
|
|
149 | (7) |
|
|
156 | (3) |
|
|
159 | (10) |
|
|
159 | (10) |
|
8 Herbal wound healing agents |
|
|
|
|
|
|
|
|
|
|
169 | (1) |
|
8.2 Wound healing agents of nonplant origins |
|
|
170 | (1) |
|
8.3 Wound healing agents of plant (herbal) origins |
|
|
171 | (8) |
|
|
179 | (1) |
|
|
179 | (6) |
|
|
180 | (1) |
|
|
181 | (4) |
|
9 Principles of applied microbiology and biotechnology: Technique for the screening of antimicrobial herbs |
|
|
|
|
M.S. Sandeep Veda Narayana |
|
|
|
|
|
|
|
|
|
|
185 | (1) |
|
9.2 General techniques of microbiology: Preparation and sterilization of media, stains, and staining techniques |
|
|
186 | (6) |
|
9.3 Classification of microbes: Actinomycetes, bacteria, rickettsiae, spirochetes, and viruses |
|
|
192 | (3) |
|
9.4 Nutrition, cultivation, isolation, and identification of bacteria, actinomycetes, fungi, viruses |
|
|
195 | (2) |
|
9.5 Control of microbes by physical and chemical methods |
|
|
197 | (11) |
|
9.6 Sterilization: Different methods, evaluation of sterilization methods, sterility testing of pharmaceutical products |
|
|
208 | (5) |
|
|
213 | (2) |
|
|
213 | (2) |
|
10 Application of nanotechnology in the packaging of edible materials |
|
|
|
|
|
|
|
|
|
|
|
215 | (1) |
|
10.2 Nanoparticles with antimicrobial properties |
|
|
216 | (2) |
|
10.3 Methods of preparing nanoparticles |
|
|
218 | (1) |
|
10.4 Nanotechnology role in packaging |
|
|
219 | (2) |
|
10.5 Practical application of nanotechnology in food packaging |
|
|
221 | (1) |
|
10.6 Brief summary of the benefits of nanotechnology application in food packaging |
|
|
222 | (1) |
|
|
222 | (7) |
|
|
223 | (6) |
|
II Health benefits of nutraceuticals |
|
|
|
11 Nutraceuticals and their impact on human health |
|
|
|
|
|
|
|
|
|
229 | (1) |
|
11.2 Types of nutraceuticals |
|
|
230 | (10) |
|
11.3 Difference between nutraceuticals and pharmaceuticals |
|
|
240 | (1) |
|
11.4 Chemical analysis of neutraceuticlas |
|
|
240 | (1) |
|
11.5 Health benefits of nutraceuticals |
|
|
240 | (5) |
|
11.6 Safety issues: Status under FDA considerations |
|
|
245 | (3) |
|
11.7 Advantages and limitations |
|
|
248 | (1) |
|
|
248 | (1) |
|
|
249 | (6) |
|
|
250 | (5) |
|
12 Heart health and nutraceuticals |
|
|
|
|
|
255 | (1) |
|
12.2 Current scenario of cardiovascular diseases |
|
|
256 | (1) |
|
12.3 Risk factors of cardiovascular diseases |
|
|
256 | (1) |
|
12.4 Preventive approach to cardiovascular diseases |
|
|
257 | (1) |
|
12.5 Nutraceuticals and current scenario |
|
|
258 | (1) |
|
12.6 Categories of nutraceuticals beneficial to heart |
|
|
259 | (5) |
|
12.7 Mechanism of action of nutraceuticals in maintaining heart health |
|
|
264 | (4) |
|
12.8 Summary and conclusion |
|
|
268 | (5) |
|
|
269 | (4) |
|
13 Roles of nutraceutical in the treatment of tuberculosis |
|
|
|
|
|
Benson Chukwunweike Ephraim-Emmanuel |
|
|
|
|
273 | (1) |
|
|
274 | (1) |
|
13.3 Epidemiology of tuberculosis |
|
|
275 | (1) |
|
13.4 Sources of vital components for health improvement |
|
|
275 | (3) |
|
|
278 | (3) |
|
|
278 | (3) |
|
14 Important food sources of nutraceuticals for the management of HIV |
|
|
|
|
|
|
281 | (1) |
|
14.2 Opportunistic illnesses in HIV infection |
|
|
282 | (1) |
|
14.3 Management of HIV and its opportunistic infections |
|
|
282 | (1) |
|
14.4 Food sources as nutraceuticals |
|
|
283 | (1) |
|
14.5 Recommended food for people with HIV/AIDS |
|
|
284 | (1) |
|
|
285 | (2) |
|
|
285 | (1) |
|
|
285 | (2) |
|
15 Nutraceuticals for male fertility in human |
|
|
|
|
|
|
287 | (1) |
|
15.2 Causes of male infertility |
|
|
288 | (1) |
|
|
289 | (1) |
|
15.4 Some important nutraceuticals |
|
|
289 | (3) |
|
|
292 | (1) |
|
|
293 | (4) |
|
|
293 | (4) |
|
16 Bacteriocin producing lactic acid bacteria: Their relevance to human nutrition and health |
|
|
|
|
|
|
|
297 | (2) |
|
|
299 | (1) |
|
|
299 | (1) |
|
16.4 Relevance of bacteriocin |
|
|
300 | (1) |
|
16.5 Summary and conclusion |
|
|
301 | (2) |
|
|
301 | (2) |
|
17 Health-promoting benefits of honey |
|
|
|
|
|
|
|
303 | (1) |
|
|
303 | (1) |
|
|
303 | (1) |
|
|
304 | (1) |
|
17.5 Biological active properties of honey |
|
|
305 | (1) |
|
17.6 New products with honey used in recent years |
|
|
305 | (1) |
|
|
306 | (2) |
|
|
306 | (2) |
|
18 Biochemical and pharmacotherapeutic potentials of lycopene in drug discovery |
|
|
|
Charles Oluwaseun Aderunji |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chioma Obianuju Peculiar-Onyekere |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
308 | (1) |
|
18.2 Biosynthesis of lycopene |
|
|
309 | (1) |
|
|
310 | (2) |
|
18.4 Metabolism of lycopene |
|
|
312 | (3) |
|
18.5 General benefits of lycopene |
|
|
315 | (1) |
|
18.6 Biological activities of lycopene and its metabolites |
|
|
316 | (16) |
|
18.7 Hair loss and male pattern balding |
|
|
332 | (2) |
|
18.8 Hepatoprotective role of lycopene against various cellular abnormalities |
|
|
334 | (3) |
|
18.9 Lycopene in human detoxification |
|
|
337 | (1) |
|
18.10 Antiinfertility properties |
|
|
338 | (1) |
|
18.11 Lycopene: Updates on clinical trials |
|
|
339 | (1) |
|
18.12 Techniques for structural elucidation of lycopene |
|
|
339 | (5) |
|
|
344 | (18) |
|
|
344 | (18) |
|
19 Health benefits of glucosinolate isolated from cruciferous and other vegetables |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
362 | (1) |
|
19.2 Impact of glucosinolates on health |
|
|
362 | (1) |
|
19.3 Pharmacological properties of glucosinolates |
|
|
363 | (6) |
|
|
369 | (4) |
|
|
370 | (3) |
|
20 Glucosamine and chondroitin in osteoarthritis treatment |
|
|
|
|
|
|
|
|
|
373 | (1) |
|
|
374 | (1) |
|
20.3 Diagnosis of osteoarthritis |
|
|
375 | (1) |
|
20.4 Treatment options to osteoarthritis |
|
|
376 | (1) |
|
20.5 Glucosamine and chondroitin |
|
|
376 | (2) |
|
20.6 Additional advantages and some known adverse events from glucosamine and chondroitin |
|
|
378 | (1) |
|
|
379 | (2) |
|
|
379 | (2) |
|
21 Phytomenadione as a dietary supplement: Sources and health benefits |
|
|
|
|
|
|
|
381 | (1) |
|
21.2 Vitamins as dietary supplements |
|
|
382 | (1) |
|
|
383 | (4) |
|
|
387 | (4) |
|
|
387 | (4) |
|
22 Application of microalgae metabolites in food and pharmaceutical industry |
|
|
|
|
|
|
|
|
391 | (1) |
|
22.2 Promising biologically active metabolites |
|
|
392 | (2) |
|
22.3 Application in pharmaceutical industry |
|
|
394 | (6) |
|
22.4 Pharmaceutical market |
|
|
400 | (1) |
|
22.5 Recent trend in food industry |
|
|
400 | (4) |
|
|
404 | (6) |
|
|
404 | (6) |
|
23 Conservation and sustainable use of medicinal plants |
|
|
|
|
|
|
|
410 | (1) |
|
23.2 Tissue culture techniques |
|
|
410 | (1) |
|
|
410 | (1) |
|
|
411 | (1) |
|
|
412 | (1) |
|
|
412 | (1) |
|
|
413 | (1) |
|
|
413 | (1) |
|
|
414 | (1) |
|
|
414 | (1) |
|
|
415 | (1) |
|
23.12 Secondary metabolites |
|
|
416 | (8) |
|
|
424 | (7) |
|
|
424 | (1) |
|
|
424 | (7) |
|
III Traditional system of medicines |
|
|
|
24 Overview of traditional systems of medicine in different continents |
|
|
|
|
|
431 | (2) |
|
24.2 Traditional systems of medicine in Asia |
|
|
433 | (32) |
|
24.3 Traditional system of medicine in the Americas |
|
|
465 | (2) |
|
24.4 Traditional system of medicine in Africa: Traditional African medicine |
|
|
467 | (3) |
|
24.5 Traditional system of medicine in Europe: European traditional medicine |
|
|
470 | (1) |
|
|
470 | (5) |
|
|
471 | (4) |
|
25 Perspective on herbal medicine in the Philippines, economic demands, quality control, and regulation |
|
|
|
|
Laurence John Francis J. Gido |
|
|
|
475 | (1) |
|
25.2 Herbal drug development in the Philippines |
|
|
476 | (2) |
|
25.3 Economic demand on herbal drugs |
|
|
478 | (2) |
|
25.4 Quality control and regulation |
|
|
480 | (1) |
|
25.5 The future of herbal medicine in the Philippines |
|
|
481 | (2) |
|
|
481 | (2) |
|
26 Traditional system of medicines in Africa |
|
|
|
|
|
|
|
483 | (1) |
|
26.2 Traditional medicines and systems of medicine in Africa |
|
|
484 | (1) |
|
26.3 Scientific evidence supporting some practices and remedies in African traditional medicine systems |
|
|
485 | (1) |
|
26.4 Regulation of traditional and alternative systems of medicine in Africa |
|
|
486 | (1) |
|
26.5 Promotion of traditional system of medicines in Africa |
|
|
486 | (1) |
|
26.6 Assessment of quality, safety, efficacy, and intellectual property rights of TM |
|
|
487 | (1) |
|
26.7 Conservation of traditional medicinal plants in Africa |
|
|
487 | (1) |
|
|
487 | (4) |
|
|
488 | (3) |
|
27 Alternative and new plants |
|
|
|
|
|
|
|
|
491 | (1) |
|
27.2 Plants replacing traditional crops |
|
|
492 | (1) |
|
27.3 Plants cultivated until the end of the 19th century |
|
|
492 | (1) |
|
|
493 | (1) |
|
|
493 | (1) |
|
27.6 Medicinal aromatherapeutic plants (MAPs) |
|
|
494 | (3) |
|
27.7 Pharmacopoeial plants |
|
|
497 | (1) |
|
27.8 Raw materials for the production of antibodies, vaccines, and medicines |
|
|
497 | (2) |
|
27.9 Raw materials for the production of functional foods |
|
|
499 | (5) |
|
|
504 | (4) |
|
27.11 Species increasing the biological diversity of food |
|
|
508 | (3) |
|
27.12 Plants useful in the greening of agriculture |
|
|
511 | (1) |
|
|
512 | (2) |
|
27.14 Renewable raw materials for industrial purposes |
|
|
514 | (3) |
|
27.15 Plants in environmental protection |
|
|
517 | (1) |
|
27.16 Plants useful in soil biological recultivation |
|
|
518 | (1) |
|
27.17 Raw materials for the production of furniture, paper, and packaging |
|
|
518 | (1) |
|
27.18 Plants that counteract the greenhouse effect |
|
|
519 | (2) |
|
27.19 Cosmetic raw materials |
|
|
521 | (2) |
|
27.20 Plants as plant protection products |
|
|
523 | (5) |
|
27.21 Transgenic plants (GMO) |
|
|
528 | (1) |
|
|
529 | (10) |
|
|
530 | (9) |
Subject Index |
|
539 | |